Frédéric Bigot

768 total citations
33 papers, 356 citations indexed

About

Frédéric Bigot is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Frédéric Bigot has authored 33 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Frédéric Bigot's work include Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Frédéric Bigot is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Frédéric Bigot collaborates with scholars based in France, Italy and Spain. Frédéric Bigot's co-authors include Christophe Massard, Eric Angevin, Aurélien Marabelle, Antoine Hollebecque, Sophie Postel‐Vinay, Capucine Baldini, Jean‐Marie Michot, Sandrine Aspeslagh, Eduardo Castañón and Andréa Varga and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Frédéric Bigot

31 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frédéric Bigot France	9	220	140	84	64	52	33	356
Ruoshuang Han China	11	212 1.0×	201 1.4×	82 1.0×	39 0.6×	65 1.3×	14	397
Joshua E. Reuss United States	13	370 1.7×	257 1.8×	51 0.6×	42 0.7×	124 2.4×	54	521
F. Rolland France	11	230 1.0×	164 1.2×	92 1.1×	41 0.6×	99 1.9×	29	457
Xiaowei Shen Canada	6	188 0.9×	108 0.8×	226 2.7×	68 1.1×	54 1.0×	10	472
Ludovic Doucet France	10	172 0.8×	185 1.3×	37 0.4×	71 1.1×	83 1.6×	37	323
Stéphane Renaud France	16	250 1.1×	390 2.8×	131 1.6×	50 0.8×	85 1.6×	42	572
Richard Mansour United States	9	152 0.7×	71 0.5×	43 0.5×	38 0.6×	40 0.8×	56	326
Laura Doni Italy	12	302 1.4×	185 1.3×	111 1.3×	72 1.1×	71 1.4×	43	434
Yan-Ping Mao China	2	364 1.7×	125 0.9×	52 0.6×	18 0.3×	34 0.7×	2	417

Countries citing papers authored by Frédéric Bigot

Since Specialization

Citations

This map shows the geographic impact of Frédéric Bigot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Bigot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Bigot more than expected).

Fields of papers citing papers by Frédéric Bigot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Bigot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Bigot. The network helps show where Frédéric Bigot may publish in the future.

Co-authorship network of co-authors of Frédéric Bigot

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Bigot. A scholar is included among the top collaborators of Frédéric Bigot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Bigot. Frédéric Bigot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bochtler, Tilmann, A. Krämer, Chantal Pauli, et al.. (2024). 200P Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study. Annals of Oncology. 35. S296–S297. 1 indexed citations

Bellesœur, Audrey, Frédéric Bigot, Antoine Angelergues, et al.. (2024). 34O ROCSAN: A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum-based chemotherapy – Preliminary results. ESMO Open. 9. 103534–103534.

Zhou, Ke, Marie Robert, Audrey Blanc-Lapierre, et al.. (2024). Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study. PLoS ONE. 19(5). e0304556–e0304556. 1 indexed citations

Abdeddaim, Cyril, Sophie Cousin, Carlos Gomez‐Roca, et al.. (2023). 758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial. Annals of Oncology. 34. S518–S518. 1 indexed citations

Molinier, Olivier, M. Marcq, Philippe Masson, et al.. (2023). A Comparative Multicenter Cohort Study Evaluating the Long-Term Influence of the Strict Lockdown during the First COVID-19 Wave on Lung Cancer Patients (ARTEMISIA Trial). Cancers. 15(24). 5729–5729. 1 indexed citations

Seegers, Valérie, Guillaume Rousseau, Ke Zhou, et al.. (2023). COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19). Cancers. 15(19). 4777–4777. 2 indexed citations

Borel, Christian, François Ghiringhelli, Frédéric Bigot, et al.. (2023). 752P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial. Annals of Oncology. 34. S515–S516. 1 indexed citations

Coutzac, Clélia, Frédéric Bigot, Damien Vansteene, et al.. (2023). 557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial. Annals of Oncology. 34. S415–S415. 3 indexed citations

Leighl, Natasha B., Luis Paz‐Ares, Delvys Rodríguez‐Abreu, et al.. (2023). 65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. Immuno-Oncology Technology. 20. 100537–100537. 8 indexed citations

10.

Coquan, Elodie, Carlos Gomez‐Roca, Aurélien Lambert, et al.. (2023). 2406P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma of the penis: Subgroup analysis of the PEVOsq basket trial. Annals of Oncology. 34. S1223–S1223. 1 indexed citations

11.

Mileshkin, Linda, Tilmann Bochtler, Chantal Pauli, et al.. (2023). LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP). Annals of Oncology. 34. S1254–S1255. 11 indexed citations

12.

Seegers, Valérie, Guillaume Rousseau, Ke Zhou, et al.. (2022). COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19). Cancers. 14(22). 5547–5547. 2 indexed citations

13.

Zhou, Ke, Audrey Blanc-Lapierre, Valérie Seegers, et al.. (2021). Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients—First Results from the PAPESCO-19 Cohort Study. Cancers. 13(14). 3389–3389. 6 indexed citations

14.

Jézéquel, Pascal, Mathieu Rubeaux, Jean‐Sébastien Frenel, et al.. (2021). The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients. BMC Cancer. 21(1). 333–333. 7 indexed citations

15.

Passot, Christophe, et al.. (2020). Caractérisation moléculaire de l’EGFR dans les cancers bronchiques non à petites cellules : étude prospective comparative des technologies NGS et automate Idylla. Annales de Pathologie. 40(5). 389–400. 8 indexed citations

16.

Bigot, Frédéric, Clément Bonnet, & Christophe Massard. (2017). Les avancées de l’immunothérapie dans la prise en charge des patients atteints de tumeurs génito-urinaires. Bulletin du Cancer. 104(4). 370–379.

17.

Bigot, Frédéric, Eduardo Castañón, Capucine Baldini, et al.. (2017). Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). European Journal of Cancer. 84. 212–218. 145 indexed citations

18.

Lanoy, Émilie, Stéphane Champiat, Jean‐Marie Michot, et al.. (2017). Long term survival in patients responding to an Anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Annals of Oncology. 28. v411–v411. 8 indexed citations

19.

Bigot, Frédéric, Antoine Hollebecque, Alberto Carmona‐Bayonas, et al.. (2016). Identification of new prognostic factors in phase I patients treated by immunotherapy. Annals of Oncology. 27. vi124–vi124. 2 indexed citations

20.

Roquelaure, Yves, Catherine Ha, Julie Bodin, et al.. (2011). Risk factors for de Quervain’s disease in a French working population. Scandinavian Journal of Work Environment & Health. 37(5). 394–401. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact